WealthShield Partners LLC Makes New Investment in IQVIA Holdings Inc. $IQV

Key Points

• WealthShield Partners acquired 11,129 IQVIA shares worth approximately $2.15 million in the second quarter. Institutional investors collectively own 89.62% of the company’s stock.
• IQVIA reported quarterly EPS of $3.15, beating estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The board also authorized a $2 billion stock buyback, covering up to 6.8% of outstanding shares.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $241.88. Meanwhile, insiders have sold 12,913 shares worth about $3.10 million over the past 90 days.

WealthShield Partners LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,129 shares of the medical research company's stock, valued at approximately $2,150,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Calamos Advisors LLC boosted its stake in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company's stock valued at $42,536,000 after acquiring an additional 137,441 shares during the last quarter. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Concurrent Investment Advisors LLC increased its stake in shares of IQVIA by 36.0% during the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company's stock worth $2,693,000 after purchasing an additional 3,161 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of IQVIA in the 4th quarter worth approximately $3,444,000. Finally, Nippon Life Global Investors Americas Inc. raised its holdings in shares of IQVIA by 36.6% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company's stock worth $17,898,000 after purchasing an additional 21,270 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In related news, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company's stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company's stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company's stock.

IQVIA Trading Up 1.6%

Shares of IQV stock opened at $260.17 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $260.40. The company has a market capitalization of $42.82 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The business's fifty day moving average is $213.32 and its 200 day moving average is $187.52.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Stifel Nicolaus upped their price target on IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price target on IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. BMO Capital Markets boosted their price objective on IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen raised shares of IQVIA from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source